Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.

Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF.

Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27.

PMID:
30262588
2.

In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease.

Uenaka T, Satake W, Cha PC, Hayakawa H, Baba K, Jiang S, Kobayashi K, Kanagawa M, Okada Y, Mochizuki H, Toda T.

Hum Mol Genet. 2018 Nov 15;27(22):3974-3985. doi: 10.1093/hmg/ddy279.

3.

Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.

Asano M, Matsui J, Towle MJ, Wu J, McGonigle S, DE Boisferon MH, Uenaka T, Nomoto K, Littlefield BA.

Anticancer Res. 2018 Jun;38(6):3375-3385. doi: 10.21873/anticanres.12604.

PMID:
29848686
4.

Less Limb Muscle Involvement in Myositis Patients with Anti-Mitochondrial Antibodies.

Uenaka T, Kowa H, Ohtsuka Y, Seki T, Sekiguchi K, Kanda F, Toda T.

Eur Neurol. 2017;78(5-6):290-295. doi: 10.1159/000481503. Epub 2017 Oct 19.

PMID:
29049993
5.

Japanese WDR45 de novo mutation diagnosed by exome analysis: A case report.

Endo H, Uenaka T, Satake W, Suzuki Y, Tachibana H, Chihara N, Ueda T, Sekiguchi K, Mariko TI, Kowa H, Kanda F, Toda T.

Neurol Clin Neurosci. 2017 Jul;5(4):131-133. doi: 10.1111/ncn3.12132. Epub 2017 Jun 29.

6.

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.

Watanabe Miyano S, Yamamoto Y, Kodama K, Miyajima Y, Mikamoto M, Nakagawa T, Kuramochi H, Funasaka S, Nagao S, Sugi NH, Okamoto K, Minoshima Y, Nakatani Y, Karoji Y, Ohashi I, Yamane Y, Okada T, Matsushima T, Matsui J, Iwata M, Uenaka T, Tsuruoka A.

Mol Cancer Ther. 2016 Nov;15(11):2630-2639. Epub 2016 Aug 17.

7.

Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61.

Huang KC, Chen Z, Jiang Y, Akare S, Kolber-Simonds D, Condon K, Agoulnik S, Tendyke K, Shen Y, Wu KM, Mathieu S, Choi HW, Zhu X, Shimizu H, Kotake Y, Gerwick WH, Uenaka T, Woodall-Jappe M, Nomoto K.

Mol Cancer Ther. 2016 Jun;15(6):1208-16. doi: 10.1158/1535-7163.MCT-15-0648. Epub 2016 Mar 29.

8.

Radiographic occult cerebellar germinoma presenting with progressive ataxia and cranial nerve palsy.

Minami N, Tanaka K, Kimura H, Hirose T, Mori T, Maeyama M, Sekiya H, Uenaka T, Nakamizo S, Nagashima H, Mizukawa K, Itoh T, Sasayama T, Kohmura E.

BMC Neurol. 2016 Jan 12;16:4. doi: 10.1186/s12883-015-0516-9.

9.

[Medial longitudinal fasciculus (MLF) syndrome in a patient with giant cell arteritis].

Uenaka T, Hamaguchi H, Sekiguchi K, Kowa H, Kanda F, Toda T.

Rinsho Shinkeigaku. 2015;55(2):107-10. doi: 10.5692/clinicalneurol.55.107. Japanese.

PMID:
25746074
10.

Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.

Bao X, Zheng W, Hata Sugi N, Agarwala KL, Xu Q, Wang Z, Tendyke K, Lee W, Parent L, Li W, Cheng H, Shen Y, Taylor N, Dezso Z, Du H, Kotake Y, Zhao N, Wang J, Postema M, Woodall-Jappe M, Takase Y, Uenaka T, Kingston DG, Nomoto K.

Cancer Biol Ther. 2015;16(4):589-601. doi: 10.1080/15384047.2015.1019184. Epub 2015 Mar 2.

11.
12.

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.

Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, Smith JJ, Porter-Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Uenaka T, Pollock RM, Kuntz KW, Yokoi A, Keilhack H.

Mol Cancer Ther. 2014 Apr;13(4):842-54. doi: 10.1158/1535-7163.MCT-13-0773. Epub 2014 Feb 21.

13.

[Reversible cerebral vasoconstriction syndrome in a stroke patient with systemic lupus erythematosus and antiphospholipid antibody].

Uenaka T, Hamaguchi H, Sekiguchi K, Kowa H, Kanda F, Toda T.

Rinsho Shinkeigaku. 2013;53(4):283-6. Japanese.

PMID:
23603542
14.

Myositis with antimitochondrial antibodies diagnosed by rectus abdominis muscle biopsy.

Uenaka T, Kowa H, Sekiguchi K, Nagata K, Ohtsuka Y, Kanda F, Toda T.

Muscle Nerve. 2013 May;47(5):766-8. doi: 10.1002/mus.23730. Epub 2013 Apr 4.

PMID:
23553600
15.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

16.

Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.

Am J Pathol. 2012 Sep;181(3):1034-43. doi: 10.1016/j.ajpath.2012.05.023. Epub 2012 Jul 9.

PMID:
22789825
17.

Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S.

Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2.

18.

Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.

Clin Cancer Res. 2012 Mar 15;18(6):1663-71. doi: 10.1158/1078-0432.CCR-11-1171. Epub 2012 Feb 8.

19.

E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.

Ogino H, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.

Mol Cancer Ther. 2011 Jul;10(7):1218-28. doi: 10.1158/1535-7163.MCT-10-0707. Epub 2011 May 6.

20.

Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.

Bruheim S, Kristian A, Uenaka T, Suo Z, Tsuruoka A, Nesland JM, Fodstad Ø.

Int J Cancer. 2011 Aug 1;129(3):742-50. doi: 10.1002/ijc.25922. Epub 2011 Mar 25.

21.

Brain imaging modality before systemic thrombolysis for ischemic stroke within three hours.

Uenaka T, Yoneda Y, Yamamoto S, Hara Y, Yamashita H.

Eur Neurol. 2010;64(4):241-5. doi: 10.1159/000319918. Epub 2010 Sep 7.

PMID:
20820106
22.

E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.

Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S.

Clin Cancer Res. 2009 Dec 1;15(23):7229-37. doi: 10.1158/1078-0432.CCR-09-1980. Epub 2009 Nov 24.

23.

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M.

Clin Cancer Res. 2008 Sep 1;14(17):5459-65. doi: 10.1158/1078-0432.CCR-07-5270.

24.

Intracloacal infection with avian infectious bronchitis virus.

Uenaka T, Kishimoto I, Sato S, Animas SB, Ito T, Otsuki K, Cook JK.

Avian Pathol. 1998;27(3):309-12. doi: 10.1080/03079459808419342.

PMID:
18484004
25.

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.

Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M.

Int J Cancer. 2008 Feb 1;122(3):664-71.

26.

Isolation and transcriptional analysis of novel tetrachloroethene reductive dehalogenase gene from Desulfitobacterium sp. strain KBC1.

Tsukagoshi N, Ezaki S, Uenaka T, Suzuki N, Kurane R.

Appl Microbiol Biotechnol. 2006 Jan;69(5):543-53. Epub 2005 Sep 20.

PMID:
16172885
27.

Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors.

Kamata J, Okada T, Kotake Y, Niijima J, Nakamura K, Uenaka T, Yamaguchi A, Tsukahara K, Nagasu T, Koyanagi N, Kitoh K, Yoshimatsu K, Yoshino H, Sugumi H.

Chem Pharm Bull (Tokyo). 2004 Sep;52(9):1071-81.

28.

Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities.

Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M.

J Antibiot (Tokyo). 2004 Mar;57(3):188-96.

29.

A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.

Nakamura K, Uenaka T, Nagasu T, Sugumi H, Yamaguchi A, Kotake Y, Okada T, Kamata J, Niijima J, Taniguchi T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K.

Cancer Sci. 2003 Jan;94(1):119-24.

30.

Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K.

Mol Cancer Ther. 2002 Jan;1(3):169-75.

31.

A monoclonal antibody, 3A10, recognizes a specific amino acid sequence present on a series of developmentally expressed brain proteins.

Harada A, Takeuchi K, Dohmae N, Takio K, Uenaka T, Aoki J, Inoue K, Umeda M.

J Biochem. 1999 Mar;125(3):443-8.

33.

A novel peptide probe for studying the transbilayer movement of phosphatidylethanolamine.

Aoki Y, Uenaka T, Aoki J, Umeda M, Inoue K.

J Biochem. 1994 Aug;116(2):291-7.

Supplemental Content

Loading ...
Support Center